SWOG clinical trial number
S9900

A Randomized Phase III Trial of Surgery Alone or Surgery Plus Preoperative Paclitaxel/Carboplatin in Clinical Stage IB(T2N0), II (T1-2N1, T3N0) and Selected IIIA (T3N1) Non-Small Cell Lung Cancer (NSCLC).

Closed
Phase
Accrual
53%
Published
Abbreviated Title
Surgery vs. Surgery/Preop Pac/Carbo in NSCLC; IB, II & selected IIIA
Activated
10/15/1999
Closed
07/15/2004
Participants
NCORP, Members, Medical Oncologists, Surgeons, Pathologists, ECOG, NCCTG, RTOG, ACOSOG, NCIC-CTG, CTSU

Research committees

Lung Cancer

Treatment

Paclitaxel Carboplatin Surgery

Eligibility Criteria Expand/Collapse

Patients must have histologically or cytologically confirmed diagnosis of Stage IB (T2N0), II (T1-2N1, T3N0) and selected Stage IIIA (T3N1) NSCLC; pts. must have measurable dz; pts. with symptomatic tumors (T3N0,N1) involving the superior sulcus (Pancoast Tumors) are ineligible; pts. must have adequate renal, hematologic, hepatic and pulmonary function as outlined in Section 5.0; no prior systemic chemo or RT; prior resection of lung dz is allowed provided at least five years have elapsed between surgery and registration; pts. must not have plans to receive non-protocol chemo, RT, or any other treatment for their cancer prior to progression of disease; pts. must not have post obstructive pneumonia or other serious infection or underlying med conditions; no prior allergic reactions to drugs containing cremophor; pts. must be suitable candidates for surgery as outlined in Section 7.0; pts. must be offered participation in S9925 (Lung Cancer Specimen Repository Protocol).

This study has been approved by NCI's Central Institutional Review Board.

Publication Information Expand/Collapse

2019

The accuracy of clinical staging of stage I-III non-small cell lung cancer: An analysis based on individual participant data [on behalf of the NSCLC Meta-analysis Collaborative Group (K Kelly)]

N Navani;D Fisher;J Tierney;S Burdett;SWOG Collaborators:;PA Bunn;E Vallieres Chest Mar;155(3):502-509

PMid: PMID30391190 | PMC number: PMC6435782

2016

Comorbidities and Risk of Chemotherapy-Induced Peripheral Neuropathy Among Participants 65 Years or Older in Southwest Oncology Group Clinical Trials

D Hershman;C Till;J Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology Sep 1;34(25):3014-3022; 2016 Jun 20 [Epub ahead of print]

PMid: PMID27325863 | PMC number: PMC5012713

Comorbidities and risk of chemotherapy induced peripheral neuropathy among participants in SWOG clinical trials

DL Hershman;C Till;JD Wright;D Awad;S Ramsey;W Barlow;L Minasian;J Unger Journal of Clinical Oncology 34, 2016 (suppl; abstr 10001); American Society of Clinical Oncology Annual Meeting (June 3-7, 2016, Chicago, IL), oral presentation

2014

Pre-operative chemotherapy for non-small cell lung cancer: a systematic review and meta-analysis of individual particpant data. [P. Bunn and K. Pisters collaborators]

S Burdett;NSCLC Meta-analysis Collab Grp Lancet 383(9928):1561-1571;

PMid: PMID24576776 | PMC number: PMC4022989

Comparison of survival outcomes among cancer patients treated in and out of clinical trials

J Unger;W Barlow;DP Martin;S Ramsey;M Leblanc;R Etzioni;D Hershman Journal of the National Cancer Institute 106(3):dju002; 2014 Mar 13 [Epub ahead of print];

PMid: PMID24627276 | PMC number: PMC3982777

2010

Surgery with or without preoperative paclitaxel and carboplatin in early-stage non-small cell lung cancer: Southwest Oncology Group S9900, an intergroup, randomized, phase III trial

KMW Pisters;E Vallieres;J Crowley;W Franklin;P Bunn;RJ Ginsberg;JB Putnam;K Chansky;DR Gandara Journal of Clinical Oncology 28(11):1843-1849;

PMid: PMID20231678 | PMC number: PMC2860367

2009

S9900 trial update, mature analysis

KM Pisters;E Vallieres;P Bunn;J Crowley;K Chansky;D Gandara Journal of Thoracic Oncology 4(9):suppl. 1, Abst. #E9.3, S201; 2009 (IASLC 13th World Conf on Lung Cancer, oral;

2008

Cooperative group research efforts in lung cancer: focus on early stage non-small cell lung cancer

H Wakelee;C Langer;E Vokes;J Schiller;P Bass;N Saijo;A Adjei;F Shepherd;H Choy;DR Gandara Clinical Lung Cancer 9(1):9-15

PMid: PMID18282352 | PMC number: (Reviews are not within the scope of the Public Access )

2007

S9900: surgery alone or surgery plus induction (ind) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): follow-up on a phase III trial

K Pisters;E Vallieres;PA Bunn;J Crowley;K Chansky;R Ginsberg;DR Gandara Proc of the American Society of Clinical Oncology, Journal of Clinical Oncology 25(18S):#7520

2005

S9900: a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC): preliminary results.

K Pisters;E Vallieres;P Bunn;J Crowley;R Ginsberg;P Ellis;B Meyers;R Marks;J Treat;D Gandara Proc of the ASCO, JCO 23(16S):624s (#LBA7012)

S9900: Preliminary "surgical" results of a phase III trial of surgery alone or surgery plus preoperative (preop) paclitaxel/carboplatin (PC) chemotherapy in early stage non-small cell lung cancer (NSCLC)

E Vallieres;KMW Pisters;J Crowley;K Chansky;P Bunn;D Gandara Lung Cancer 49 (Suppl 2):S43 (0-124)

1999

Preoperative chemotherapy in stage III non-small cell lung cancer: long -term outcome

DR Gandara;B Leigh;E Vallieres;KS Albain Lung Cancer 26:3-6

Other Clinical Trials

SWOG Clinical Trial Number
S2414

INcorporating pathologic reSponse in patIents with early staGe lung cancer to optimize immunotHerapy in the adjuvanT setting (INSIGHT)

Research Committee(s)
Lung Cancer
Symptom Control and Quality of Life
Activated
03/14/2025
Accrual
1%
Open
Phase
SWOG Clinical Trial Number
CTSU/NRG-LU007